Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Melanoma 51Neoplasm Metastasis 19Skin Neoplasms 15Carcinoma, Renal Cell 13Leukemia, Myeloid, Acute 12Kidney Neoplasms 11Leukemia 9Neoplasms 7Uterine Cervical Neoplasms 5Lymphoma 5Congenital Abnormalities 5Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neuroblastoma 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Carcinoma, Non-Small-Cell Lung 4Vaginal Neoplasms 2Penile Neoplasms 2Papillomavirus Infections 2Oropharyngeal Neoplasms 2Melanoma, Experimental 2Lymphoma, Mantle-Cell 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Erythroblastic, Acute 2Brain Neoplasms 2

Interventions

Temozolomide 47Bevacizumab 41Radiotherapy 17Magnetic Resonance Spectroscopy 14Irinotecan 11Nivolumab 8Everolimus 7Radiation 6poly ICLC 5X-Rays 5Phantoms, Imaging 5Carboplatin 5pembrolizumab 4fluorodopa F 18 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Granulocyte-Macrophage Colony-Stimulating Factor 4Erlotinib Hydrochloride 4Carmustine 4ribociclib 3palbociclib 3ivosidenib 3antineoplaston A10 3Vorinostat 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Modafinil 3Lomustine 3Biopsy 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioma × aldesleukin × Clear all
NCT01454596 2019-08-21

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
18 enrolled 25 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡